Could the GI tract be a better portal for antibody therapy?

Green, S. J.; Brendsel, Jon
November 2006
Gut;Nov2006, Vol. 55 Issue 11, p1681
Academic Journal
The article explains the possibility of the gastrointestinal tract to be a better portal for antibody therapy. It has been reported that the infusion of fontolizumab, an anti-interferon antibody, into patients with Crohn's disease was generally well tolerated with encouraging clinical responses. It was observed that oral was as effective as intravenous administration of anti-CD3 in reversing experimental autoimmune encephalomyelitis.


Related Articles

  • Interfering with interferons in inflammatory bowel disease. Ghosh, S.; Chaudhary, R.; Carpani, M.; Playford, R. // Gut;Aug2006, Vol. 55 Issue 8, p1071 

    The article discusses the use of interferons for the treatment of inflammatory bowel disease. Interferons show antitumor and antiviral activities. In inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, there is an increase in plasma and tissue concentrations of...

  • The Action of Interferon at the Molecular Level. Baglioni, Corrado; Nilsen, Timothy W. // American Scientist;Jul/Aug81, Vol. 69 Issue 4, p392 

    Examines the antiviral defense mechanism of interferon, a substance produced in the body in response to infection, for possible therapeutic applications. Problems associated with interferon; Synthesis of specific enzymes; Basis for the application of interferon as an antiviral drug.

  • Interferon signatures in immune disorders and disease. Forster, Samuel // Immunology & Cell Biology;May/Jun2012, Vol. 90 Issue 5, p520 

    The interferon (IFN) family and the type-I IFNs specifically have an important and well-characterized role in antiviral defence, immune modulation and cell-cycle control and are regularly applied in the clinical context. Advances in high-content technologies have facilitated an enhanced...

  • Antiviral TRIMs: friend or foe in autoimmune and autoinflammatory disease? Jefferies, Caroline; Wynne, Claire; Higgs, Rowan // Nature Reviews Immunology;Sep2011, Vol. 11 Issue 9, p617 

    The concept that viral sensing systems, via their ability to drive pro-inflammatory cytokine and interferon production, contribute to the development of autoimmune and autoinflammatory disease is supported by a wide range of clinical and experimental observations. Recently, the tripartite...

  • What options do we have for induction therapy for Crohn's disease?  // Inflammatory Bowel Disease Monitor;2011, Vol. 11 Issue 3, p130 

    The article discusses the availability of induction therapies for Crohn's disease and the factors that affect the choice of induction treatment for patients. It notes that a chronic inflammatory process characterizes Crohn's disease that can affect any part of the gastrointestinal tract. It...

  • Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Yao-Chun Hsu; Ho, Hsiu J.; Yen-Tsung Huang; Hsi-Hao Wang; Ming-Shiang Wu; Jaw-Town Lin; Chun-Ying Wu // Gut;Mar2015, Vol. 64 Issue 3, p495 

    Objective: To elucidate the association between antiviral therapy and extrahepatic outcomes in individuals infected with HCV. Methods: This nationwide cohort study screened 293 480 Taiwanese residents with HCV infection and excluded those with substantial comorbidity. A total of 12 384 eligible...

  • Interferon-associated retinopathy. Savant, V; Gillow, T // Eye;May2003, Vol. 17 Issue 4, p534 

    Eye (2003) 17, 534-536. doi:10.1038/sj.eye.6700391

  • Enhanced anti-HCV activity of interferon alpha 17 subtype. Dubois, Aurelie; Fran├žois, Catherine; Descamps, Veronique; Fournier, Carole; Wychowski, Czeslaw; Dubuisson, Jean; Castelain, Sandrine; Duverlie, Gilles // Virology Journal;2009, Vol. 6, p1 

    Background: Pegylated interferon alpha 2 (a or b) plus ribavirin is the most effective treatment of chronic hepatitis C but a large proportion of patients do not respond to therapy. So, it is interesting to improve the treatment efficacy. Interferon alpha is a type I interferon composed of 12...

  • Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Wong, John B.; Davis, Gary L.; McHutchison, John G.; Manns, Michael P.; Albrecht, Janice K. // American Journal of Gastroenterology;Nov2003, Vol. 98 Issue 11, p2354 

    : ObjectivesEvaluation of 12-wk viral response to initial antiviral therapy for chronic hepatitis C has been recommended to minimize antiviral-associated morbidity and costs. The aim of this study was to examine the economic and clinical effects of evaluating rapid viral response during...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics